Companies › NGNE

NEUROGENE INC (NGNE)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001404644 · EDGAR filings · Updated 2026-07-07

NEUROGENE INC (NGNE) has reported institutional ownership of 109.0%, with 96 institutional managers holding positions valued at $342.0M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01).

Latest updates

• 2026-07-07 — Insider transaction reported (Form 4)
• 2026-07-02 — Insider transaction reported (Form 4)
• 2026-07-02 — Current report (8-K) filed
• 2026-07-02 — Prospectus supplement (424B5) filed
• 2026-06-30 — Prospectus supplement (424B5) filed
• 2026-06-29 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, NEUROGENE INC has 96 institutional holders and institutional ownership of 109.0%.

Insider activity

Insiders reported 15 transactions (0 buys, 11 sells) across 4 reporting insiders, with a net reported value of −$596.5K.

Data flags from SEC filings

Related companies

NEUROPACE INC (NPCE) · ROCKET PHARMACEUTICALS I (RCKT) · BENITEC BIOPHARMA INC (BNTC) · PRIME MEDICINE INC (PRME) · MONOPAR THERAPEUTICS INC (MNPR) · AURA BIOSCIENCES INC (AURA)